EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of Transglutaminase 2 as a Therapeutic Strategy in Celiac Disease—In Vitro Studies in Intestinal Cells and Duodenal Biopsies

Sebastian Stricker iD, Jan de Laffolie, Klaus-Peter Zimmer, Silvia Rudloff

International Journal of Molecular Sciences · 01.03.2023 · 24 (5) · 4795

DOI: 10.3390/ijms24054795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.03.2023. Verfasst von Sebastian Stricker und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Justus-Liebig-University Giessen, 35392 Giessen, Germany. Hauptthemen laut MEDLINE: Celiac Disease, Protein Glutamine gamma Glutamyltransferase 2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, University Medical Center Giessen and Marburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enzymatic modification of gliadin peptides by human transglutaminase 2 (TG2) is a key mechanism in the pathogenesis of celiac disease (CD) and represents a potential therapeutic target. Recently, we have identified the small oxidative molecule PX-12 as an effective inhibitor of TG2 in vitro. In this study, we further investigated the effect of PX-12 and the established active-site directed inhibitor ERW1041 on TG2 activity and epithelial transport of gliadin peptides. We analyzed TG2 activity using immobilized TG2, Caco-2 cell lysates, confluent Caco-2 cell monolayers and duodenal biopsies from CD patients. TG2-mediated cross-linking of pepsin-/trypsin-digested gliadin (PTG) and 5BP (5-biotinamidopentylamine) was quantified by colorimetry, fluorometry and confocal microscopy. Cell viability was tested with a resazurin-based fluorometric assay. Epithelial transport of promofluor-conjugated gliadin peptides P31-43 and P56-88 was analyzed by fluorometry and confocal microscopy. PX-12 reduced TG2-mediated cross-linking of PTG and was significantly more effective than ERW1041 (10 µM, 15 ± 3 vs. 48 ± 8%, p < 0.001). In addition, PX-12 inhibited TG2 in cell lysates obtained from Caco-2 cells more than ERW1041 (10 µM; 12 ± 7% vs. 45 ± 19%, p < 0.05). Both substances inhibited TG2 comparably in the intestinal lamina propria of duodenal biopsies (100 µM, 25 ± 13% vs. 22 ± 11%). However, PX-12 did not inhibit TG2 in confluent Caco-2 cells, whereas ERW1041 showed a dose-dependent effect. Similarly, epithelial transport of P56-88 was inhibited by ERW1041, but not by PX-12. Cell viability was not negatively affected by either substance at concentrations up to 100 µM. PX-12 did not reduce TG2 activity or gliadin peptide transport in confluent Caco-2 cells. This could be caused by rapid inactivation or degradation of the substance in the Caco-2 cell culture. Still, our in vitro data underline the potential of the oxidative inhibition of TG2. The fact that the TG2-specific inhibitor ERW1041 reduced the epithelial uptake of P56-88 in Caco-2 cells further strengthens the therapeutic potential of TG2 inhibitors in CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Celiac DiseaseProtein Glutamine gamma Glutamyltransferase 2HumansBiopsyCaco-2 CellsGliadinIntestinal MucosaPeptidesTransglutaminasesIntestines

Stichwörter der Autor:innen

PX-12TG2 inhibitorceliac diseasegliadin transporttransglutaminase 2

Substanzen

GliadinPeptidesProtein Glutamine gamma Glutamyltransferase 2Transglutaminases

Autor:innen und Institutionen

  • Department of Pediatrics, Justus-Liebig-University Giessen, 35392 Giessen, Germany.
  • Institute of Nutritional Science, Justus-Liebig-University Giessen, 35392 Giessen, Germany.

ORCID-Profile: Sebastian Stricker

Förderung

  • Deutsche Forschungsgemeinschaft
  • University Medical Center Giessen and Marburg

Zitieren

APA

Stricker, S., de Laffolie, J., Zimmer, K. P., & Rudloff, S. (2023). Inhibition of Transglutaminase 2 as a Therapeutic Strategy in Celiac Disease—In Vitro Studies in Intestinal Cells and Duodenal Biopsies. International Journal of Molecular Sciences, 24(5), 4795. https://doi.org/10.3390/ijms24054795

Vancouver

Stricker S, de Laffolie J, Zimmer KP, Rudloff S. Inhibition of Transglutaminase 2 as a Therapeutic Strategy in Celiac Disease—In Vitro Studies in Intestinal Cells and Duodenal Biopsies. International Journal of Molecular Sciences. 2023;24(5):4795. doi:10.3390/ijms24054795

BibTeX
@article{Stricker2023,
  author = {Stricker, Sebastian and de Laffolie, Jan and Zimmer, Klaus-Peter and Rudloff, Silvia},
  title = {Inhibition of Transglutaminase 2 as a Therapeutic Strategy in Celiac Disease—In Vitro Studies in Intestinal Cells and Duodenal Biopsies},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {5},
  pages = {4795},
  doi = {10.3390/ijms24054795}
}
Kostenlos starten →